Walgreen is being pressed by investors to increase its share buyback activity, sources close to the situation told TheStreet.
Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.
Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.
Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.
U.S. stock futures are mixed; a report says Allergan approached Salix and at least one other company about a potential acquisition; Citigroup weighs sale of Japan unit.
Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.
Is Rite Aid a buy right now or are Walgreens and CVS Caremark a better investment?
DepoMed (DEPO) is gaining Tuesday after the U.S. District Court for the District of New Jersey ruled in favor of the drug manufacturer in is patent lawsuit against Actavis (ACT).
Apple, Amarin and Zynga are our big swing trades for today. So how should investors buy and sell?
Spectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established.
The founder of the Silicon Valley startup Eaze is moving ahead of launch Moio Direct, despite legal concerns.
Mallinckrodt (MNK) is gaining Friday after beating analysts’ estimates for earnings and revenue in the fiscal third quarter and news that it will join the S&P 500.
MannKind signed a $925 million licensing pact with French drug maker Sanofi this week to sell its diabetes drug Afrezza.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Raptor released positive phase 3 data for its Huntington's treatment in February, but since then little has happened. The share price is now depressed, presenting a good entry point.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV